|
(ÁÖ)¾Æ¹ÌÆÊ |
ÁÖ½Äȸ»ç ¾Æ¹ÌÆÊ - CRA ä¿ë °ø°í
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
05.02 |
|
|
(ÁÖ)Ƽ¾Ø¾Ë¹ÙÀÌ¿ÀÆÕ |
RA ÀÇ·á±â±â ÀÓ»ó ´ã´çÀÚ ¸ðÁý
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.29 |
|
|
PPD Development Pte. Ltd. |
SCRA ¹× CRA II ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
06.07 |
|
|
A&T Consulting |
Clinical Research Associate
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
10.10 |
|
|
InnoHR |
±Û·Î¹ú Á¦¾à»ç CRA 2³â ÀÌ»ó
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.18 |
|
|
Å©¸®½ºÅ»Áö³ë¹Í½º(ÁÖ) |
ÀÓ»óPM ¹× ÀÓ»óCRA °æ·ÂÁ÷ ä¿ë
°æ±â ¼º³²½Ã ºÐ´ç±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.20 |
|
|
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ |
(ÁÖ)½Ã¹ÍÄÚ¸®¾Æ CRA I, II, Sr. °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
11.28 |
|
|
ICON Clinical Research Korea |
Study Start-up Associate
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
ICON Clinical Research Korea |
Jr. Clinical Research Associate(Oncology)
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
¾ÆÀÌÄÜŬ¸®´ÏÄø®¼Ä¡ |
Global CRO ICON Korea CRA II / Sr. Contract & Grant Anal
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
½á³ÊÀκñÀÚ |
CRA ÇÁ¸®·£¼ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
06.20 |
|
|
Å©¸®½ºÅ»Áö³ë¹Í½º(ÁÖ) |
ÀÓ»óPM / ÀÓ»óCRA / ÀÓ»óRA °æ·ÂÁ÷ ä¿ë
°æ±â ¼º³²½Ã ºÐ´ç±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
01.29 |
|
|
(ÁÖ)»çÀ̳ؽº |
ÀǾàÇ°/ÀÇ·á±â±â ÀÓ»ó °³¹ß º»ºÎ PM
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
»ó½Ãä¿ë |
03.22 |
|
|
À̳ëºê·¹ÀÎ |
Senior Quality Standards Associate Ãʺù
¼¿ï °ºÏ±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
12.07 |
|
|
ÆĹ̼¿(ÁÖ) |
ÆĹ̼¿(ÁÖ) ÀÓ»óÆÀ °æ·ÂÁ÷ ä¿ë°ø°í
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
01.19 |
|